Install
Ophthalmology & Vision
Glaucoma, cataracts, macular degeneration, and eye‑care technology updates.
- 3 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Respiratory & Pulmonology
- Gastroenterology & Hepatology
- Endocrinology & Hormones
- Nephrology & Urology
- Dermatology
- Rheumatology & Autoimmune
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Ophthalmology & Vision
Vertical Pupil Elongation, Poor Dilation Risk Factors for Intraoperative Floppy Iris Syndrome
14+ hour, 33+ min ago (478+ words) Review of Optometry...
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
7+ hour, 33+ min ago (422+ words) GlobeNewswire...
Okogen Secures CDSCO Authorization for EMERALD Phase 1/2 Study of Treyegen™ (OKG-0303) for Acute Infectious Conjunctivitis
3+ hour ago (339+ words) citybuzz - Okogen, Inc., a clinical-stage biotechnology company developing innovative therapies for infectious diseases, announced on October 6, 2026, that the Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, has authorized the EMERALD study. This Phase 1/2 clinical trial will evaluate…...
LASIK in Bozeman: Laser Vision Correction for Montana’s Active Patients
1+ hour, 57+ min ago (164+ words) BOZEMAN, MT - October 06, 2026 - PRESSADVANTAGE - With outdoor pursuits including skiing, fly fishing, trail running, and mountain biking forming part of daily life for many Montanans, interest in laser vision correction has remained a consistent topic of patient inquiry at the Bozeman…...
SXTP: Hospital study remains blinded; expanded access results and 2027 unblinding are next
1+ hour, 35+ min ago (70+ words) TradingView SXTP: Hospital study remains blinded; expanded access results and 2027 unblinding are next The DSMB recommended completing the blinded hospital study, with no safety signal; follow-up of 30 patients is planned before unblinding in early 2027. The first three expanded access patients…...
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
7+ hour, 20+ min ago (246+ words) OKYO Pharma announces enrollment of first patients in Phase 3 trial evaluating urcosimod for neuropathic corneal pain treatment. The NEPTUNE trial is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain. Dr. Melissa Toyos at Toyos Clinic in Nashville,…...
Eye implant triggers sight improvements in GA at 36-months, pivotal study finds
3+ hour, 59+ min ago (333+ words) These results come as the FDA currently mulls PRIMA’s fate on the US ophthalmic device market. Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to patients with a degenerative…...
New World Medical Receives MDR Certification for Ahmed® Glaucoma Valve, Ahmed ClearPath®, and KDB GLIDE®
3+ hour, 45+ min ago (226+ words) Oct 06, 2026, 10:44 ET This important milestone reflects the company's ongoing commitment to advancing glaucoma care and expanding access to vision-preserving treatment options for surgeons and patients globally. "We are proud to reach this important milestone for New World Medical," said Raymond…...
ZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAO
5+ hour, 33+ min ago (653+ words) ZEISS Medical Technology will showcase its latest innovations and digital technologies at AAO, including: Connected cataract workflow –ZEISS VERACITY Surgery Planner reaches 3 million surgical cases planned through cloud-based software, supporting surgical efficiency built on automation and accurate data. Celebrating 1 million…...
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
3+ hour, 38+ min ago (377+ words) Proactive has a commercial relationship with OKYO Pharma Ltd. This article was produced independently under Proactive's Editorial Standards Policy. OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to announce a major clinical development milestone, with the first patients…...